Search results
Forecast: Analysts Think Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Business Prospects Have...
Simply Wall St. via Yahoo Finance· 7 months agoCelebrations may be in order for Adaptimmune Therapeutics plc (NASDAQ:ADAP) shareholders, with the...
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc...
Simply Wall St. via Yahoo Finance· 2 years agoCelebrations may be in order for Adaptimmune Therapeutics plc (NASDAQ:ADAP) shareholders, with the...
News Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP)...
Simply Wall St. via Yahoo Finance· 1 year agoAdaptimmune Therapeutics plc (NASDAQ:ADAP) shareholders will have a reason to smile today, with the...
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
Zacks via Yahoo Finance· 4 months agoThe most recent trading session ended with Adaptimmune Therapeutics PLC (ADAP) standing at $1.20,...
Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even...
Simply Wall St. via Yahoo Finance· 11 months agoIt's nice to see the Adaptimmune Therapeutics plc (NASDAQ:ADAP) share price up 12% in a week. But...
Hedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP)...
Simply Wall St. via Yahoo Finance· 2 years agoEvery investor in Adaptimmune Therapeutics plc (NASDAQ:ADAP) should be aware of the most powerful...
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business
Simply Wall St. via Yahoo Finance· 2 years agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) are in the red if they invested five years...
Simply Wall St. via Yahoo Finance· 2 years agoAdaptimmune Therapeutics plc (NASDAQ:ADAP) shareholders should be happy to see the share price up...
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive But Perhaps Not Attractive Enough
Simply Wall St. via Yahoo Finance· 1 year agoWith a price-to-sales (or "P/S") ratio of 8.5x Adaptimmune Therapeutics plc (NASDAQ:ADAP) may be...
Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights
Zacks via Yahoo Finance· 8 months agoIn the latest market close, Adaptimmune Therapeutics PLC (ADAP) reached $0.55, with a -1.79%...